JP2021519089A5 - - Google Patents
Info
- Publication number
- JP2021519089A5 JP2021519089A5 JP2020551924A JP2020551924A JP2021519089A5 JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5 JP 2020551924 A JP2020551924 A JP 2020551924A JP 2020551924 A JP2020551924 A JP 2020551924A JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- protein complex
- complex according
- based chimeric
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024006808A JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649248P | 2018-03-28 | 2018-03-28 | |
| US201862649238P | 2018-03-28 | 2018-03-28 | |
| US201862649264P | 2018-03-28 | 2018-03-28 | |
| US62/649,264 | 2018-03-28 | ||
| US62/649,238 | 2018-03-28 | ||
| US62/649,248 | 2018-03-28 | ||
| PCT/US2019/024714 WO2019191519A1 (en) | 2018-03-28 | 2019-03-28 | Bi-functional proteins and construction thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Division JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519089A JP2021519089A (ja) | 2021-08-10 |
| JP2021519089A5 true JP2021519089A5 (cg-RX-API-DMAC7.html) | 2022-04-05 |
Family
ID=68060793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551924A Pending JP2021519089A (ja) | 2018-03-28 | 2019-03-28 | 二官能性タンパク質およびその作製 |
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210024631A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773674A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021519089A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260100427A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112512551A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019243580A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095310A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019191519A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| KR102642385B1 (ko) * | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| CN117924493A (zh) * | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| CA3090406A1 (en) * | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| EP3890773A4 (en) * | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| CN113840833B (zh) * | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ,インコーポレイテッド | 治療用インターフェロンアルファ1タンパク質 |
| JP7729778B2 (ja) * | 2019-03-28 | 2025-08-26 | オリオニス バイオサイエンシズ,インコーポレイテッド | Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体 |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Il13を含む融合タンパク質 |
| JPWO2020250706A1 (cg-RX-API-DMAC7.html) | 2019-06-12 | 2020-12-17 | ||
| US11636771B2 (en) | 2019-09-08 | 2023-04-25 | Deere & Company | Stackable housing containers and related systems |
| CA3163358A1 (en) | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021144415A1 (en) * | 2020-01-17 | 2021-07-22 | Universiteit Gent | Immunoglobulin single domain antibodies for delivery of mucosal vaccines |
| JP7512413B2 (ja) * | 2020-03-31 | 2024-07-08 | ビオテウス・インコーポレイテッド | 抗pd-l1およびpd-l2抗体ならびにその誘導体および用途 |
| WO2021230460A1 (ko) * | 2020-05-14 | 2021-11-18 | 주식회사 제넥신 | Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도 |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022093857A1 (en) * | 2020-10-26 | 2022-05-05 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| WO2022089418A1 (zh) * | 2020-10-26 | 2022-05-05 | 信达生物制药(苏州)有限公司 | 重组截短FLT3配体与人抗体Fc的融合蛋白 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| WO2022133094A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Fap binding molecules and uses thereof |
| WO2022221746A1 (en) * | 2021-04-16 | 2022-10-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| WO2023016564A1 (zh) * | 2021-08-12 | 2023-02-16 | 上海才致药成生物科技有限公司 | 靶向GPC3的抗体干扰素α融合蛋白及其用途 |
| TW202319397A (zh) * | 2021-08-30 | 2023-05-16 | 美商英伊布里克斯公司 | NKp46結合多肽及其用途 |
| TW202328171A (zh) * | 2021-08-30 | 2023-07-16 | 美商英伊布里克斯公司 | 靶向NKp46之經修飾之IL-2多肽及其用途 |
| CN118317785A (zh) * | 2021-09-13 | 2024-07-09 | 根特大学 | 氨肽酶n特异性单克隆抗体及其用途 |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| US12559576B2 (en) * | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| CN119403568A (zh) * | 2022-04-07 | 2025-02-07 | 艾丽塔生物治疗剂公司 | 用于治疗癌症的组合物和方法 |
| WO2023201051A2 (en) * | 2022-04-15 | 2023-10-19 | Palleon Pharmaceuticals Inc. | Anti-inflammatory siglec-6 proteins and methods of making and using same |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN116286844A (zh) * | 2023-02-13 | 2023-06-23 | 浙江大学 | 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途 |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| IL327059A (en) * | 2023-09-11 | 2026-05-01 | Shanghai Btd Bio Tech Co Ltd | A long-acting fusion protein that is an agonist for the parathyroid hormone receptor, and its use |
| CN122422358A (zh) * | 2023-11-17 | 2026-07-17 | 奥里尼斯生物科学有限公司 | 基于pd-l1的嵌合蛋白制剂 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327199D1 (de) * | 2002-04-26 | 2009-05-28 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening auf agonistische antikörper |
| EP2343081A1 (en) * | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| EP4169525A1 (en) * | 2011-07-08 | 2023-04-26 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| PL2822575T3 (pl) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| PE20170908A1 (es) * | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| EP3371311B1 (en) * | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11370826B2 (en) * | 2016-02-09 | 2022-06-28 | Bracco Suisse Sa | Recombinant chimeric protein for selectins targeting |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2019
- 2019-03-28 KR KR1020267018744A patent/KR20260100427A/ko active Pending
- 2019-03-28 CN CN201980035145.6A patent/CN112512551A/zh active Pending
- 2019-03-28 KR KR1020207031008A patent/KR20210005872A/ko not_active Ceased
- 2019-03-28 AU AU2019243580A patent/AU2019243580A1/en not_active Abandoned
- 2019-03-28 EP EP19775640.6A patent/EP3773674A4/en active Pending
- 2019-03-28 JP JP2020551924A patent/JP2021519089A/ja active Pending
- 2019-03-28 WO PCT/US2019/024714 patent/WO2019191519A1/en not_active Ceased
- 2019-03-28 CA CA3095310A patent/CA3095310A1/en active Pending
- 2019-03-28 US US17/042,512 patent/US20210024631A1/en active Pending
-
2024
- 2024-01-19 JP JP2024006808A patent/JP2024028543A/ja active Pending
-
2025
- 2025-05-28 AU AU2025203995A patent/AU2025203995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Kontermann | Dual targeting strategies with bispecific antibodies | |
| EP3443006B1 (en) | Trispecific and/or trivalent binding proteins | |
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| JP2023123649A5 (cg-RX-API-DMAC7.html) | ||
| JP2021118723A5 (cg-RX-API-DMAC7.html) | ||
| JP7486810B2 (ja) | IgG1 Fcモノマー、及びその使用 | |
| JP2022511135A (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JP2020036595A5 (cg-RX-API-DMAC7.html) | ||
| JP2024521405A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2002033073A1 (ja) | 低分子化アゴニスト抗体 | |
| CA2411374A1 (en) | Dual specificity antibodies and methods of making and using | |
| JP2023526282A5 (cg-RX-API-DMAC7.html) | ||
| JP2022544785A5 (cg-RX-API-DMAC7.html) | ||
| US20230272110A1 (en) | Antibodies that bind psma and gamma-delta t cell receptors | |
| JP2025508882A5 (cg-RX-API-DMAC7.html) | ||
| US20200181263A1 (en) | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa | |
| CN116284396B (zh) | NKp46抗体及其用途 | |
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| Rossi et al. | Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α | |
| US20110165122A1 (en) | Method for targeted and sustained antiviral therapy | |
| JP2022550345A5 (cg-RX-API-DMAC7.html) | ||
| WO2001079494A1 (fr) | Anticorps agonistes | |
| RS64771B1 (sr) | Trispecifični i/ili trovalentni vezujući proteini |